Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04957719 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

Study acronym: SOS-AMI
StatusEnrolling by Invitation
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Dec 2026 → Jul 2027
See other at-risk trials from Viatris Innovation GmbH

Record History

The 50 most recent of 63 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Dec 2026 to Jul 2027 Trial sites expanded: 813 → 821 locationsv63 Show 1 more changeShow less
    • Trial sites expanded: 813 → 821 locations
  2. Re-verified, no change to tracked fieldsv62
  3. Trial sites expanded: 786 → 813 locationsv61
  4. Trial sites expanded: 738 → 786 locationsv60
  5. Enrollment increased: 14000 → 25000 participants Eligibility criteria shortened, about 5 wordsv59 Show 1 more changeShow less
    • Eligibility criteria shortened, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  6. Trial sites expanded: 716 → 738 locationsv58
  7. Study sites: 696 to 716v57
  8. Study sites: 703 to 696v56
  9. Study sites: 619 to 703v55
  10. Study sites: 586 to 619v54
  11. Study sites: 563 to 586v53
  12. Study sites: 520 to 563v52
  13. Primary and study completion dates: Aug 13, 2025 to Dec 2026 Study sites: 489 to 520v51 Show 1 more changeShow less
    • Study sites: 489 to 520
  14. Study sites: 478 to 489v50
  15. Lead sponsor: Idorsia Pharmaceuticals Ltd. to Viatris Innovation GmbH Study sites: 461 to 478v49 Show 1 more changeShow less
    • Study sites: 461 to 478
  16. Study sites: 449 to 461v48
  17. Study sites: 438 to 449v47
  18. Eligibility criteria expanded, about 16 wordsv46 See this version in full on ClinicalTrials.gov ↗
  19. Study sites: 425 to 438v45
  20. Study sites: 416 to 425v44
  21. Study sites revised (416)v43 See this version in full on ClinicalTrials.gov ↗
  22. Study sites: 395 to 416v42
  23. Study sites: 374 to 395v41
  24. Study sites: 361 to 374v40
  25. Study sites: 353 to 361v39
  26. Primary and study completion dates: Sep 28, 2026 to Aug 13, 2025 Study sites: 346 to 353v38 Show 1 more changeShow less
    • Study sites: 346 to 353
  27. Primary and study completion dates: Aug 2025 to Sep 28, 2026v37
  28. Study sites: 342 to 346v36
  29. Study sites: 335 to 342v35
  30. Study sites: 326 to 335v34
  31. Study sites: 314 to 326v33
  32. Study sites: 313 to 314v32
  33. Re-verified, no change to tracked fieldsv31
  34. Study sites: 317 to 313v30
  35. Study sites: 313 to 317v29
  36. Study sites: 315 to 313 Eligibility criteria expanded, about 9 wordsv28 Show 1 more changeShow less
    • Eligibility criteria expanded, about 9 words

    See this version in full on ClinicalTrials.gov ↗

  37. Re-verified, no change to tracked fieldsv27
  38. Study sites revised (315)v26 See this version in full on ClinicalTrials.gov ↗
  39. Study sites: 310 to 315v25
  40. Study sites revised (310)v24 See this version in full on ClinicalTrials.gov ↗
  41. Study sites revised (310)v23 See this version in full on ClinicalTrials.gov ↗
  42. Study sites: 305 to 310v22
  43. Study sites: 306 to 305v21
  44. Study sites: 305 to 306v20
  45. Re-verified, no change to tracked fieldsv19
  46. Study sites revised (305)v18 See this version in full on ClinicalTrials.gov ↗
  47. Study sites: 304 to 305v17
  48. Study sites: 306 to 304v16
  49. Study sites: 225 to 306v15
  50. Study sites: 211 to 225v14
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.
Trial Details
NCT Number NCT04957719
Lead Sponsor Viatris Innovation GmbH
Conditions Acute Myocardial Infarction
Enrollment 25,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov